This is a randomized blinded trial of whether hospitalized smokers who are randomly assigned
to receive bupropion, an antidepressant, and cognitive-behavioral counseling, are more likely
to have quit smoking at the end of treatment and at 6 months compared with smokers randomly
assigned to receive placebo and cognitive-behavioral counseling. Because depression is more
prevalent among smokers and because smokers who are prone to depression may become depressed
when they quit, the hypothesis is that the proportion of quitters who receive the active
drug/antidepressant will be greater than the proportion of quitters who receive the placebo
drug at 6 months.